Questcor Pharmaceuticals, Inc.
3260 Whipple Road
Union City,
CA 94587
United States - Map
Phone: 510-400-0700
Fax: 510-400-0799
Web Site: http://www.questcor.com
| Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Don M. Bailey , 63
Chief Exec. Officer, Pres |
$
954.00K |
$
2.79M | Mr. Gary M. Sawka , 62
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. |
$
111.00K | N/A | Mr. Neal C. Bradsher ,
Director, Chairman of Nominating & Corp. Governance Committee and Pres of Broadwood Capital Inc |
$
52.00K | N/A | Dr. David Young Pharm.D., Ph.D.,, 56
Chief Scientific Officer, Director, Chairman of FDA Matters Oversight Committee, Chairman of Compensation Committee, Member of Audit Committee, Member of Nominating & Corp. Governance Committee and Pres of AGI Therapeutics Inc |
$
70.00K | N/A | Mr. David J. Medeiros , 57
Sr. VP of Pharmaceutical Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
Profile
